Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy

Dr. Anubhab Mukherjee completed his Ph.D. from the CSIR-Indian Institute of Chemical Technology, Hyderabad, India, having been skilled with RNAi, liposomal drug delivery in cancer, preclinical cell, and animal studies. He pursued post-doctoral research at the College of Pharmacy, Health Science Center, Texas A&M University, and was involved in another postdoctoral research at Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, California. In 2015, he worked at the Harvard-MIT Health Sciences and Technology as a visiting scientist. He has substantial experience in nanotechnology-based formulation development and successfully worked for various Indian organizations to develop pharmaceuticals and nutraceutical formulations. He is an inventor of many U.S. patents and an author of many peer-reviewed articles published in various international journals of repute. Dr. Mukherjee is currently serving as Principal Scientist, R&D at Esperer Onco Nutrition (EON) Pvt. Ltd. and heads the Hyderabad R&D center of the organization.Dr. Vijay Sagar Madamsetty received his Ph.D. in chemical science from the Academy of Scientific and Innovative Research (AcSIR), India. He has had a passion for developing cutting-edge research on nanomedicine for about ten years, starting from the Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) and continuing to the present as a senior postdoctoral fellow at the Mayo Clinic Florida in the Department of Biochemistry and Molecular Biology. He is currently developing multiple drugs/genes encapsulating targeted nanoformulations and their preclinical evaluation in several dis ease animal models. Dr. Madamsetty's long-term research inter ests involve understanding key signaling pathways and how alterations in gene expression contribute to human diseases, leading to developing effective targeted nanomedicine. He is also an active reviewer and editorial board member of several international journals.Dr. Sudip Mukherjee completed his Ph.D. from the CSIR-Indian Institute of Chemical Technology, Hyderabad, India. Dr. Mukherjee is currently working as a Postdoctoral Research Associate at Rice University. His research is involved in the development of advanced nanomaterials for drug/gene delivery in cancer theranostics, immunomodulatory applications, and angiogenesis. He has published a total of ~50 research articles/patents. He serves as International Advisory Board Member for "Materials Research Express," IOP Sciences. He is a member (MRSC) of RSC, UK. He serves as reviewer for several international journals such as ChemComm, Journal of Materials Chemistry A, Journal of Materials Chemistry B, Journal of Biomedical Nanotechnology, RSC Advances, and IOP Nanotechnology, Biofabrication.

Introduction.- Immune Response and Its Role in Cancer.- Immunomodulation and Various Strategies Effecting Immune Response.- Immunomodulatory Organic and Polymer Nanomedicine in Cancer Therapy.- Immunomodulatory Liposomes in Cancer Therapy.- Immunomodulatory Protein Nanoparticles in Cancer Therapy ' Immunomodulatory Viral Nanoparticles in Cancer Therapy.- Authors' Biographies.